At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 8 enrolled
Drug / intervention
ch806biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Single Dose Escalation Trial of ch806 in Patients With Advanced Tumours Expressing the 806 Antigen
In Brief
A Phase 1 clinical trial evaluating ch806 for Neoplasms. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to describe the toxicity, biodistribution, pharmacokinetics and tumour uptake of a single infusion of ch806 (tagged with a trace amount of radioactive 111-Indium: 111In-ch806) in patients with advanced tumours expressing the 806 antigen.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2005
First PostedFeb 2006
Primary CompletionFeb 2006
Study CompletionAug 2006
TodayJul 2026
First PostedFeb 14, 2006
Enrollment StartMay 1, 2005
Primary CompletionFeb 16, 2006
Study CompletionAug 10, 2006
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.4 years ago
Interventions
ch806biological
ch806 is a chimeric (part human, part mouse) antibody which recognizes and attaches to a protein called the 806 antigen (a type of EGFR), which is found on the surface of some cancer cells.